Table 1.
Patient characteristics
| Normal kidney function (H) | CKD 3 | CDK 4–5 | |
|---|---|---|---|
| Subjects | n = 19 | n = 15 | n = 13 |
| Mean eGFR (mL/min/1.73m2) | 88 | 47 | 20 |
| Mean Age (years) | 66 | 76 | 74 |
| Sex ratio Female/Male | 31%F (6F/13M) | 13%F (2F/13M) | 40% (5F/8M) |
| Smoking | 32% (6/19) | 20%(3/15) | 8% (1/13) |
| Diabetes mellitus 2 | 21% (4/19) | 40% (6/15) | 69% (9/13) |
| STEMI | 47% (9/19) | 47% (7/15) | 46% (6/13) |
| Non-STEMI | 52% (10/19) | 53% (8/15) | 54% (7/13) |
| Angiography before sampling | 89% (17/19) | 85% (11/15) | 77% (10/13) |
| PCI before sampling | 68% (13/19) | 40% (6/15) | 69% (9/13) |
| Angiography after sampling | 5% (1/19) | 20% (3/15) | 15% (2/13) |
| No angiography | 5% (1/19) | 7% (1/15) | 8% (1/13) |
| PCI anytime | 74% (14/19) | 47% (7/15) | 77% (10/13) |
| Hypertension | 58% (11/19) | 93% (14/15) | 100% (13/13) |
| Chronic ischemic heart disease | 26% (5/19) | 47% (7/15) | 69% (9/13) |
| Sample day | Mean 2.6 | Mean 2.6 | Mean 3.9 |
| Medications: | |||
| Acetylsalicylic acid | 95% (18/19) | 93% (14/15) | 100% (13/13) |
| P2Y12 receptor antagonists | 100% | 100% | 100% (13/13) |
| Clopidogrel | 84% (16/19) | 85% (11/15) | 92%(12/13) |
| Ticagelor | 11% (2/19) | 20% (3/15) | 15%(2/13) |
| Prasugrel | 5% (1/19) | 7% (1/15) | 0% (0) |
| LMWH | 42% (8/19) | 53% (8/15) | 23% (3/13) |
| Warfarin | 0 | 0 | 8% (1/13) |
| NOAK | 0 | 0 | 0 |
| Statin | 84% (16/19) | 87% (13/15) | 85% (11/13) |
| Laboratory parameters: | |||
| Mean Platelet count 109/L | 212 ± 57 | 188 ± 54 | 205 ± 83 |
| Mean Leucocyte count 109/L | 9,0 ± 2.7 | 7.6 ± 1.3 | 11.5 ± 5.7 |
| Mean p-albumin (g/L) | 35 ± 3 | 33 ± 3 | 30 ± 7 |
| Mean p-phosphate (mmol/L) | 1.06 ± 0.16 | 1.05 ± 0.15 | 1.22 ± 0.37 |